Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2021 · 10-Q
Revenue$78.84M$78.84M−0.4% vs Q3 2020 Net Income$8.05M$8.05M−28.7% vs Q3 2020 EPS Diluted$0.22$0.22−31.3% vs Q3 2020 Gross Profit$46,113,000−4.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$17,254,000−49.5% Free Cash Flowderived$16,978,000−46.6% Margins · derivedGross margin58.5%−2.4 pt vs Q3 2020
Operating margin17.9%−6.8 pt vs Q3 2020
Net margin10.2%−4.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 4, 2021 · 35 d after period end